Antisera-Neutralizing Capacity of a Highly Evolved Type 2 Vaccine-Derived Poliovirus from an Immunodeficient Patient
Viruses · 2024
DOI: 10.3390/v16111761 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Yanan Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Vaccine Research and Development for Major Infectious Diseases in Yunnan Province, Institute of Medical Biology, Chinese Academy of…. Hauptthemen laut MEDLINE: Poliovirus, Antibodies, Neutralizing, Poliovirus Vaccine, Oral, Antibodies, Viral. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Project of Medical and Health Science and Technology Innovation, Chinese Academy of Medical Sciences.
Abstract (Originalsprache)
Background
The serotype 2 oral poliovirus vaccine (OPV2) can revert to regain wild-type neurovirulence and spread, causing the emergence of vaccine-derived poliovirus (VDPV2) and immunodeficiency-related vaccine-derived polioviruses (iVDPVs). In the United States, testing carried out by the CDC of type II iVDPV (iVDPV2) with human immune serum from the vaccine has shown that the presence of the virus poses a threat to eradication efforts.
Methods
We analyzed the major neutralization sites of VP1, VP2, and VP3 of the iVDPV using bioinformatics techniques and homology modeling (SWISS-MODEL). The three amino acid residues 679, 680, and 141 of the P1 region changed, which had an impact on the spatial conformation of the viral-neutralizing site. We tested polio-vaccinated human sera and rabbit anti-Sabin II polyantibodies against a panel of iVDPV pseudoviruses.
Results
The results demonstrated that the serum’s capacity to neutralize mutant pseudoviruses diminished when amino acid substitutions were introduced into the P1 encapsidated protein, particularly when 141 and 679 were mutated together. This study emphasizes the significance of continually monitoring individuals who are known to be immunocompromised and maintaining high vaccination rates in OPV-using communities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Vaccine Research and Development for Major Infectious Diseases in Yunnan Province, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650000, China.
- Institute of Medical Biology, Kunming Medical University, Kunming 650500, China.
- Department of Industrial Transformation, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650000, China.
- Production Department, Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650000, China.
Förderung
- Project of Medical and Health Science and Technology Innovation, Chinese Academy of Medical Sciences
Zitieren
APA
Wu, Y., Zhang, R., Yuan, G., He, L., Dai, X., Chuan, H., Wang, M., Liu, J., Xu, L., Liao, G., Li, W., & Zhou, J. (2024). Antisera-Neutralizing Capacity of a Highly Evolved Type 2 Vaccine-Derived Poliovirus from an Immunodeficient Patient. Viruses. https://doi.org/10.3390/v16111761
Vancouver
Wu Y, Zhang R, Yuan G, He L, Dai X, Chuan H, et al. Antisera-Neutralizing Capacity of a Highly Evolved Type 2 Vaccine-Derived Poliovirus from an Immunodeficient Patient. Viruses. 2024. doi:10.3390/v16111761
BibTeX
@article{Wu2024,
author = {Wu, Yanan and Zhang, Runfang and Yuan, Guangbo and He, Lingyu and Dai, Xiaohu and Chuan, Hongyun and Wang, Mingqing and Liu, Jing and Xu, Lilan and Liao, Guoyang and Li, Weidong and Zhou, Jian},
title = {Antisera-Neutralizing Capacity of a Highly Evolved Type 2 Vaccine-Derived Poliovirus from an Immunodeficient Patient},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16111761}
}
EUVIMED